

AMENDMENTS TO THE CLAIMS

This listing of the claims replaces all prior listings and versions:

1 to 18. (canceled).

19. (previously presented): A method for immunizing a vertebrate subject against at least one selected antigen, the method comprising the step of parenterally administering to the vertebrate subject an immunologically effective amount of

- a) a parenteral adjuvant comprising a detoxified mutant of an *E. coli* heat-labile (LT) ADP-ribosylating toxin in combination with a pharmaceutically acceptable vehicle, wherein said detoxified mutant is LT-R72; and
- b) at least one selected antigen.

20 to 24. (canceled).

25. (previously presented): A method according to claim 19, wherein the adjuvant and the antigen are administered subcutaneously, transcutaneously or intramuscularly.

26. (original): A method according to claim 19, wherein the pharmaceutically acceptable vehicle is a topical vehicle.

27. (original): A method according to claim 26, wherein the adjuvant and the antigen are administered transcutaneously.

28. (original): A method according to claim 19, wherein the adjuvant is administered to the vertebrate subject prior to administering the selected antigen.

29. (original): A method according to claim 19, wherein the adjuvant is administered to the vertebrate subject subsequent to administering the selected antigen.

30. (original): A method according to claim 19, wherein the antigen is administered to the vertebrate subject concurrent with administering the selected antigen.

31. (previously presented): The method of claim 19, wherein said antigen is a viral antigen.

32. (currently amended): The method of claim 31, wherein said viral antigen is selected from the group consisting of an influenza antigen, ~~an~~ a herpes simplex virus (HSV) antigen, ~~an~~ a human immunodeficiency virus (HIV) antigen, a cytomegalovirus (CMV) antigen, ~~an~~ a hepatitis C virus (HCV) antigen, ~~an~~ a delta hepatitis virus (HDV) antigen, a poliovirus antigen, ~~an~~ a hepatitis A virus (HAV) antigen, an Epstein-Barr virus (EBV) antigen, a varicella zoster virus (VZV) antigen, and a respiratory syncytial virus (RSV) antigen.

33. (previously presented): The method of claim 32, wherein said viral antigen is an influenza virus antigen.

34. (previously presented): The method of claim 32, wherein said viral antigen is a poliovirus antigen.

35. (previously presented): The method of claim 32, wherein said viral antigen is a RSV antigen.

36. (currently amended): The method of claim ~~34~~ 19, wherein said antigen is a bacterial antigen.

37. (currently amended): The method of claim 36, wherein said bacterial antigen is selected from the group consisting of *Bordetella pertussis* antigens, *Helicobacter pylori* antigens, ~~streptococcal antigens~~, meningococcus A antigens, meningococcus B antigens, and meningococcus C antigens.

38. (previously presented): The method of claim 37, wherein said bacterial antigen is a *Bordetella pertussis* antigen.

39. (previously presented): The method of claim 37, wherein said bacterial antigen is an *Helicobacter pylori* antigen.

40. (canceled).

41. (previously presented): The method of claim 37, wherein said bacterial antigen is a meningococcus A antigen.

42. (previously presented): The method of claim 37, wherein said bacterial antigen is a meningococcus B antigen.

43. (previously presented): The method of claim 37, wherein said bacterial antigen is a meningococcus C antigen.